View expert perspective videos and downloadable slides from our satellite symposium at the Annual European Hematology Congress in Stockholm. This activity will help to enhance your understanding of acute myeloid leukemia (AML) in order to provide optimal treatment strategies using standard as well as new/emerging agents.
1.0 AMA PRA Category 1 Credit™
Jul 7, 2018
Jul 7, 2019
Jorge Cortes, MDThe University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Bob Löwenberg, MD, PhDErasmus University Medical Center
Rotterdam, the Netherlands
Nigel Russell, MDNottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Adriano Venditti, MDUniversity of Rome "Tor Vergata"
Drilling down on the genomic landscape of AML
Adriano Venditti, MD
Initial therapy for patients with de novo AML
Bob Löwenberg, MD, PhD
Initial therapy for patients with secondary AML
Jorge Cortes, MD
Strategies for relapsed/refractory AML
Nigel Russell, MD
Jorge Cortes, MD
This educational activity is specifically designed to meet the needs of hematologists, oncologists, and other healthcare professionals involved in the management of patients with AML.
After successful completion of this educational activity, participants should be able to:
- Develop treatment strategies for patients with AML using standard therapies as well as new/emerging agents
- Differentiate the factors that impact treatment choice among de novo, secondary, and relapsed/refractory AML
- Discuss efficacy and safety data of new/emerging treatment options that may be useful for patients with AML, and determine how these agents may best fit into treatment plans
This activity is supported by an educational grant from Jazz Pharmaceuticals.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the post-test are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Cortes has disclosed that he has received consulting fees from Bristol-Meyers Squibb, Fusion, Novartis, Pfizer, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Löwenberg has disclosed that he has received consulting fees from Clear Creek Bio Pharma. He has also disclosed participation in advisory boards for AbbVie, Agios, Astellas, and Celgen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Russell has disclosed that he has received honorarium from Jazz Pharmaceuticals for a promotional speaker’s bureau. He has also disclosed membership on advisory committees or review panels for Daiichi Sankyo, Jazz Pharmaceuticals, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Venditti has disclosed that he has served as a board member for Celgene, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, Pfizer, and Sandoz. He has also received consulting fees from Celgene, Janssen, Novartis, Pfizer, and Sandoz. He has disclosed independent contracting for Sandoz and speaking and teaching engagements for Novartis and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Onology have disclosed:
- Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
- Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
- Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationship
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.